相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Peptide-based PET imaging agent of tumor TIGIT expression
Dinghu Weng et al.
EJNMMI RESEARCH (2023)
Anti-TIGIT therapies for solid tumors: a systematic review
A. Rousseau et al.
ESMO OPEN (2023)
Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
Odrade Gondry et al.
JOURNAL OF NUCLEAR MEDICINE (2023)
TIGIT is a key inhibitory checkpoint receptor in lymphoma
James Godfrey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
J. Niu et al.
ANNALS OF ONCOLOGY (2022)
Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers
Xiaobo Wang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Byoung Chul Cho et al.
LANCET ONCOLOGY (2022)
TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer
Yaping Chen et al.
FRONTIERS IN IMMUNOLOGY (2022)
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Eugene Y. Chiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis
Hiromitsu Asashima et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Travis Shaffer et al.
CLINICAL CANCER RESEARCH (2021)
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
Quentin Lecocq et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
A comprehensive comparison between camelid nanobodies and single chain variable fragments
Yasaman Asaadi et al.
BIOMARKER RESEARCH (2021)
TIGIT as an emerging immune checkpoint
H. Harjunpaa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer
Danhua Xu et al.
IMMUNOBIOLOGY (2020)
Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours
Pieterjan Debie et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma
Zhi-Zhang Yang et al.
CLINICAL CANCER RESEARCH (2020)
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
Adi Reches et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation
Sheng Xiao et al.
CELL REPORTS (2020)
Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
Jessica Bridoux et al.
BIOMOLECULES (2020)
Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages
Catarina Xavier et al.
MOLECULAR IMAGING AND BIOLOGY (2019)
Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma
Gustav Stalhammar et al.
CANCER MEDICINE (2019)
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Mathieu Grapin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
Katrijn Broos et al.
CANCERS (2019)
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
Quentin Lecocq et al.
BIOMOLECULES (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Theranostics in immuno-oncology using nanobody derivatives
Quentin Lecocq et al.
THERANOSTICS (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Alice L. Hung et al.
ONCOIMMUNOLOGY (2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
A. N. Niemeijer et al.
NATURE COMMUNICATIONS (2018)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT)
Felix A. Deuss et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
Katrijn Broos et al.
ONCOTARGET (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Antibody Aggregation: Insights from Sequence and Structure
Wei Li et al.
ANTIBODIES (2016)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
Man Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
M. Lemaire et al.
LEUKEMIA (2014)
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
Noa Stanietsky et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
The tumor microenvironment at a glance
Frances R. Balkwill et al.
JOURNAL OF CELL SCIENCE (2012)
In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT
Ilse Vaneycken et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Kent S. Boles et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)